{
  "kind": "treatment",
  "slug": "venlafaxine-effexor",
  "type": "medication",
  "name": "Venlafaxine",
  "summary": "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, and panic disorders.",
  "description": "Venlafaxine, marketed under the brand name Effexor, is an SNRI antidepressant that works by increasing the levels of serotonin and norepinephrine in the brain, helping to improve mood and reduce anxiety symptoms. It is prescribed for major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. The extended-release formulation allows once-daily dosing for improved adherence.",
  "category": "medications/psychiatry",
  "tags": [
    "antidepressant",
    "SNRI",
    "anxiety",
    "depression",
    "panic disorder"
  ],
  "metadata": {
    "drug_classes": [
      "Antidepressant",
      "SNRI"
    ],
    "therapeutic_categories": [
      "Psychiatry"
    ],
    "mechanism_categories": [
      "SNRI"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Effexor",
      "Effexor XR"
    ],
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Long-term maintenance"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary care"
    ],
    "fda_approval_year": 1993
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression",
      "Anxiety"
    ],
    "off_label_uses": [
      "Migraine prophylaxis",
      "Hot flashes associated with menopause"
    ],
    "contraindications": [
      "Use with MAO inhibitors or within 14 days of discontinuation",
      "Hypersensitivity to venlafaxine or desvenlafaxine"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Mood and suicidal ideation",
      "Signs of serotonin syndrome",
      "Renal and hepatic function"
    ],
    "efficacy_rating": {
      "Major depressive disorder": 3,
      "Generalized anxiety disorder": 3,
      "Panic disorder": 3,
      "Social anxiety disorder": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "venlafaxine",
      "Effexor",
      "SNRI antidepressant"
    ],
    "synonyms": [
      "Effexor",
      "venlafaxine hydrochloride"
    ],
    "common_misspellings": [
      "venlaxafine",
      "venlafaxin",
      "venalafaxine"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major depressive disorder",
        "Generalized anxiety disorder",
        "Panic disorder",
        "Social anxiety disorder"
      ]
    },
    {
      "type": "mechanism",
      "text": "Inhibits the reuptake of serotonin and norepinephrine, increasing their availability in the synaptic cleft, which helps regulate mood and anxiety."
    },
    {
      "type": "dosing",
      "adult": {
        "oral": "Immediate-release: Start at 37.5–75 mg/day in divided doses; may increase by 75 mg/day at intervals of 4 days or more; maximum 375 mg/day. Extended-release: Start at 37.5–75 mg once daily; may increase by 75 mg/day at intervals of 4 days or more; maximum 225 mg/day for depression and anxiety."
      },
      "pediatric": {
        "oral": "Safety and efficacy not established for most indications."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets (immediate-release): 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg",
        "Extended-release capsules: 37.5 mg, 75 mg, 150 mg, 225 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Initial improvement may be seen in 1–2 weeks, with full therapeutic effects typically achieved within 4–8 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "dry mouth",
        "sweating",
        "insomnia",
        "somnolence",
        "dizziness",
        "constipation"
      ],
      "less_common": [
        "sexual dysfunction",
        "tremor",
        "blurred vision",
        "weight changes"
      ],
      "serious": [
        "hypertension",
        "serotonin syndrome",
        "suicidal ideation",
        "angle-closure glaucoma",
        "seizures"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "May increase blood pressure; monitor regularly",
        "Risk of serotonin syndrome, especially with other serotonergic drugs",
        "May cause discontinuation symptoms if stopped abruptly; taper gradually",
        "Monitor for worsening depression or suicidality, especially early in treatment"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAO inhibitors",
          "risk": "Serotonin syndrome",
          "action": "Contraindicated"
        },
        {
          "with": "Other serotonergic agents",
          "risk": "Increased serotonin syndrome risk",
          "action": "Monitor closely"
        },
        {
          "with": "NSAIDs or anticoagulants",
          "risk": "Increased bleeding risk",
          "action": "Monitor for bleeding"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Blood pressure",
        "Mood and suicidal ideation",
        "Signs of serotonin syndrome",
        "Renal and hepatic function"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if potential benefit justifies potential risk; consider neonatal monitoring for withdrawal symptoms",
      "lactation": "Excreted in human milk; monitor infants for adverse effects",
      "geriatrics": "Monitor for hyponatremia and increased sensitivity to side effects"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce the dose over at least 1–2 weeks to minimize withdrawal symptoms such as dizziness, insomnia, and irritability."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Effective in both depression and anxiety spectrum disorders",
        "Extended-release formulation may improve adherence and reduce side effects",
        "Monitor closely for blood pressure changes, especially at higher doses"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Effexor XR Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "NHS - Venlafaxine",
          "url": "https://www.nhs.uk/medicines/venlafaxine/"
        },
        {
          "label": "PubChem - Venlafaxine",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Venlafaxine"
        }
      ]
    }
  ],
  "seo": {
    "title": "Venlafaxine (Effexor) - Uses, Dosage, Side Effects, and Warnings",
    "description": "Venlafaxine (Effexor) is an SNRI antidepressant for depression and anxiety disorders. Learn about dosing, side effects, interactions, and precautions."
  }
}
